טוען...
Minimal residual disease in acute myelogenous leukemia
Treatment of acute myelogenous leukemia (AML) over the past four decades remains mostly unchanged and the prognosis for the majority of patients remains poor. Most of the significant advances that have been observed are in defining cytogenetic abnormalities, as well as the genetic and epigenetic pro...
שמור ב:
| הוצא לאור ב: | Int J Lab Hematol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5652069/ https://ncbi.nlm.nih.gov/pubmed/28447422 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijlh.12670 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|